Vanda Pharmaceuticals Inc (VNDA)
4.845
+0.18
(+3.97%)
USD |
NASDAQ |
Nov 04, 16:00
4.845
0.00 (0.00%)
After-Hours: 20:00
Vanda Pharmaceuticals Gross Profit Margin (Quarterly): 94.59% for June 30, 2024
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 94.59% |
| March 31, 2024 | 92.75% |
| December 31, 2023 | 92.36% |
| September 30, 2023 | 92.11% |
| June 30, 2023 | 92.40% |
| March 31, 2023 | 92.36% |
| December 31, 2022 | 90.33% |
| September 30, 2022 | 90.32% |
| June 30, 2022 | 90.59% |
| March 31, 2022 | 90.59% |
| December 31, 2021 | 90.83% |
| September 30, 2021 | 90.30% |
| June 30, 2021 | 90.33% |
| March 31, 2021 | 90.38% |
| December 31, 2020 | 90.52% |
| September 30, 2020 | 90.22% |
| June 30, 2020 | 90.60% |
| March 31, 2020 | 91.02% |
| December 31, 2019 | 89.78% |
| September 30, 2019 | 88.60% |
| June 30, 2019 | 89.22% |
| March 31, 2019 | 89.28% |
| December 31, 2018 | 89.32% |
| September 30, 2018 | 89.69% |
| June 30, 2018 | 88.99% |
| Date | Value |
|---|---|
| March 31, 2018 | 89.54% |
| December 31, 2017 | 89.18% |
| September 30, 2017 | 89.05% |
| June 30, 2017 | 89.23% |
| March 31, 2017 | 89.30% |
| December 31, 2016 | 86.21% |
| September 30, 2016 | 81.84% |
| June 30, 2016 | 81.98% |
| March 31, 2016 | 82.09% |
| December 31, 2015 | 80.62% |
| September 30, 2015 | 77.03% |
| June 30, 2015 | 79.10% |
| March 31, 2015 | 77.36% |
| December 31, 2014 | 95.56% |
| September 30, 2014 | 95.24% |
| June 30, 2014 | 98.18% |
| March 31, 2014 | |
| December 31, 2013 | |
| September 30, 2013 | |
| June 30, 2013 | |
| March 31, 2013 | |
| December 31, 2012 | |
| September 30, 2012 | |
| June 30, 2012 | |
| March 31, 2012 |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
89.78%
Minimum
Dec 2019
94.59%
Maximum
Jun 2024
91.18%
Average
90.59%
Median
Jun 2022
Gross Profit Margin (Quarterly) Benchmarks
| Zevra Therapeutics Inc | 19.69% |
| Edgewise Therapeutics Inc | -- |
| NovaBay Pharmaceuticals Inc | 66.33% |
| Palatin Technologies Inc | -- |
| iBio Inc | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -2.01% |
| Return on Assets | -1.69% |
| Return on Invested Capital | -2.01% |
| Profit Margin (Quarterly) | -8.95% |
| Operating Margin (Quarterly) | -20.10% |
| Return on Net Operating Assets | -8.78% |